Clindesse

Babesiosis, Mitral Valve Prolapse, Toxoplasmosis + 39 more

Treatment

20 Active Studies for Clindesse

What is Clindesse

Clindamycin

The Generic name of this drug

Treatment Summary

Clindamycin is a type of antibiotic that can be used to treat a range of bacterial infections. It is most effective against anaerobic bacteria, gram-positive cocci and bacilli, and gram-negative bacilli. It can also be used off-label to treat protozoal infections such as toxoplasmosis, malaria, and babesiosis. Clindamycin is a semi-synthetic form of lincomycin, a naturally occurring antibiotic discovered in soil samples from Lincoln, Nebraska. It is a more effective form of the drug, and it has largely replaced lincomycin in

Cleocin Hydrochloride

is the brand name

image of different drug pills on a surface

Clindesse Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cleocin Hydrochloride

Clindamycin

1970

507

Effectiveness

How Clindesse Affects Patients

Clindamycin is an antibiotic that stops the growth of bacteria. It needs to be taken every 6 hours to work properly. Clindamycin can cause severe diarrhea, especially in those who use it for a long time. It can also cause overgrowth of a dangerous bacteria, _Clostridium difficile_. Therefore, it should only be used to treat serious infections when other, less toxic drugs won't work. Clindamycin works against a variety of bacteria, including both gram-positive and gram-negative anaerobes. However, resistance to clindamycin can develop, so it's important to

How Clindesse works in the body

Clindamycin prevents bacteria from reproducing by stopping their proteins from being made. It does this by blocking the bacterial ribosome's ability to assemble and translate the proteins. Clindamycin's shape is similar to certain molecules in the bacteria, which helps it to interfere with their protein production. We don't know exactly how it helps to clear up acne, but it may have something to do with its ability to fight the bacteria that causes it.

When to interrupt dosage

The suggested measure of Clindesse is contingent upon the diagnosed disorder, including viridans group streptococci, Vaginal Infections and Surgical Intervention. The degree of dosage can be found in the following table, depending on the method of delivery (e.g. Cream - Vaginal or Suspension - Topical).

Condition

Dosage

Administration

Babesiosis

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Toxoplasmosis

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Endometritis caused by Anaerobic Bacterial Infection

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

prophylaxis of Bacterial endocarditis

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Malaria

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Acne Vulgaris

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Acquired Immunodeficiency Syndrome

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Acne Vulgaris

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Endocarditis, Bacterial

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Heart Valve Prosthesis

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Candidiasis, Vulvovaginal

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Surgical Intervention

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Vaginal Infections

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Bacterial Vaginosis

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Bacteria, Anaerobic

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Skin Structures and Soft Tissue Infections caused by susceptible streptococci

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Communicable Diseases

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Bacteria, Anaerobic

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Respiratory Tract Infections (RTI) caused by susceptible streptococci

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Respiratory Tract Infections

150.0 mg, 300.0 mg, , 0.02 mg/mg, 75.0 mg/mL, 150.0 mg/mL, 75.0 mg, 0.01 mg/mg, 10.0 mg/mL, 6.0 mg/mL, 12.0 mg/mL, 18.0 mg/mL, 100.0 mg/mL, 10.0 mg, 0.1 mg/mg, 100.0 mg, 1.0 %, 1.2 %, 30.0 mg/mL, 60.0 mg/mL, 90.0 mg/mL, 0.012 mg/mg, 11.9 mg/mL, 5.0 mg/mg, 0.007 mg/mg, 0.01 mg/mL

, Capsule - Oral, Oral, Capsule, Vaginal, Cream, Cream - Vaginal, Granule, for solution, Granule, for solution - Oral, Injection, solution, concentrate, Intravenous, Injection, solution, concentrate - Intravenous, Topical, Gel - Topical, Gel, Suspension, Suspension - Topical, Solution, Solution - Topical, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Swab, Swab - Topical, Kit, Kit - Topical, Aerosol, foam, Aerosol, foam - Topical, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Lotion, Lotion - Topical, Suppository, Suppository - Vaginal, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit - Intramuscular; Intravenous, Powder, for solution - Oral, Powder, for solution, Solution - Intramuscular; Intravenous, Liquid, Liquid - Intramuscular; Intravenous, Solution - Intravenous, Cream - Topical, Injection, Injection - Intravenous, Injection - Intramuscular; Intravenous, Injection, solution, concentrate - Intramuscular; Intravenous, Kit - Infiltration; Intramuscular; Intravenous, Infiltration; Intramuscular; Intravenous, Gel - Vaginal

Warnings

Clindesse has four contraindications. It should not be administered when dealing with any of the conditions shown in the following table.

Clindesse Contraindications

Condition

Risk Level

Notes

Enterocolitis, Pseudomembranous

Do Not Combine

Crohn Disease

Do Not Combine

Ulcerative Colitis

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Clindamycin may interact with Pulse Frequency

There are 20 known major drug interactions with Clindesse.

Common Clindesse Drug Interactions

Drug Name

Risk Level

Description

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Clindamycin.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Clindamycin.

Bromocriptine

Major

The serum concentration of Bromocriptine can be increased when it is combined with Clindamycin.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Clindamycin.

Cabergoline

Major

The serum concentration of Cabergoline can be increased when it is combined with Clindamycin.

Clindesse Toxicity & Overdose Risk

The most toxic dose of clindamycin in mice was 2540mg/kg and in rats it was 2190mg/kg. There have not been any reports of overdose yet, but symptoms could include abdominal pain, nausea, vomiting, and diarrhea. In clinical trials, one 3-year-old child was given a daily dose of 100mg/kg for 5 days and only had mild stomach pain and diarrhea. Activated charcoal can be used to help remove unabsorbed drug, but dialysis is not effective. General supportive care is recommended in cases of clindamycin overdose.

image of a doctor in a lab doing drug, clinical research

Clindesse Novel Uses: Which Conditions Have a Clinical Trial Featuring Clindesse?

73 active trials are being conducted to assess the potential of Clindesse in providing Bacterial Endocarditis, Acne and Pneumocystis Jirovecii Pneumonia relief.

Condition

Clinical Trials

Trial Phases

Respiratory Tract Infections (RTI) caused by susceptible streptococci

0 Actively Recruiting

Acne Vulgaris

5 Actively Recruiting

Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Mitral Valve Prolapse

1 Actively Recruiting

Not Applicable

Hypertrophic Cardiomyopathy

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Surgically constructed systemic-pulmonary shunt

0 Actively Recruiting

Respiratory Tract Infections

0 Actively Recruiting

Bacteria, Anaerobic

0 Actively Recruiting

Heart Defects, Congenital

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Bone and Bones

0 Actively Recruiting

Babesiosis

1 Actively Recruiting

Phase 2

Mixed Vaginal Infections

0 Actively Recruiting

Toxoplasmosis

1 Actively Recruiting

Phase 4

Surgical Intervention

0 Actively Recruiting

Pelvic cellulitis caused by Anaerobic Bacterial Infection

0 Actively Recruiting

Bacterial Endocarditis

0 Actively Recruiting

Malaria

0 Actively Recruiting

Acne Vulgaris

0 Actively Recruiting

Vaginal Infections

0 Actively Recruiting

Acquired Immunodeficiency Syndrome

39 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 4

Clindesse Reviews: What are patients saying about Clindesse?

5

Patient Review

12/17/2014

Clindesse for Vaginosis caused by Bacteria

Cleocin did not help with the burning or pain associated with my bacterial vaginosis and, in fact, made it much worse. It also caused nausea and stomach pains. I'm now trying boric acid suppositories at the recommendation of my doctor.

5

Patient Review

10/19/2022

Clindesse for Vaginosis caused by Bacteria

I didn't experience any of the negative side effects I read about before taking this medication. There was some light discharge for the first few days, but nothing a liner couldn't handle. All in all, this treatment was very successful and only cost me $125 with insurance.

5

Patient Review

4/22/2014

Clindesse for Vaginosis caused by Bacteria

I am using the vaginal insert, not the pill. How long until the odor is gone?

5

Patient Review

1/18/2016

Clindesse for Vaginosis caused by Bacteria

Worked very quickly and overnight as advertised. The horrible smell was gone by the morning, which is a huge relief. I usually get bacterial vaginosis (BV) constantly, and my doctor usually prescribes me Flagyl; however, that always makes me violently ill. With this product, I only had mild pelvic pain and white, clumpy discharge; but it's way better than explosive and painful diarrhea.

4.7

Patient Review

10/22/2015

Clindesse for Vaginosis caused by Bacteria

Though it may make sex feel quite uncomfortable, this medication really helped me clear up a tough bacterial infection. I had tried other prescribed medications to no avail, but Clindesse did the trick within just a day or so.

4.3

Patient Review

5/25/2018

Clindesse for Vaginosis caused by Bacteria

I'm on day six of this medication, and while it was easy enough to administer, the itching has been driving me up the wall. The discharge is still present, but there does seem to be a reduction in odor.

3.7

Patient Review

1/30/2009

Clindesse for Vaginosis caused by Bacteria

3.7

Patient Review

8/17/2011

Clindesse for Vaginosis caused by Bacteria

I had severe abdominal pain after taking this medication, to the point where I thought it might be from my period. However, even after my period ended, the pain persisted. This stuff is not worth it in my opinion.

2

Patient Review

8/7/2014

Clindesse for Vaginosis caused by Bacteria

This worked well for me.

2

Patient Review

4/4/2017

Clindesse for Vaginosis caused by Bacteria

Unfortunately, this medication didn't provide any relief for me. In fact, I think it made things worse.

1

Patient Review

10/27/2016

Clindesse for Vaginosis caused by Bacteria

I had been struggling with bacterial vaginosis for four years before I finally found Clindesse. This medication cleared up my symptoms in just a month and I haven't had any issues since!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about clindesse

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Clindesse an antibiotic?

"Clindesse is a single-dose antibiotic cream used to treat bacterial vaginosis (vaginal infections caused by certain bacteria) in non-pregnant women. Clindesse Cream works by slowing the growth of these bacteria."

Answered by AI

Does Clindesse cause yeast infection?

"If these effects persist or worsen, stop using this product and consult your doctor or pharmacist.

Although mild stomach upset is uncommon, it may occur. If your symptoms persist or worsen, consult your doctor or pharmacist. You may have a new vaginal infection if you experience discomfort, burning, itching, or discharge. These symptoms may worsen while using this product. If your symptoms persist or worsen, stop using the product and consult your doctor or pharmacist."

Answered by AI

How long does Clindesse stay in the vagina?

"If you have sex while the mineral oil is still in your vagina, your condom or vaginal diaphragm could break.

The mineral oil in Clindesse (clindamycin) can make latex products like condoms and vaginal diaphragms weaker. It stays in your vagina for 5 days after you use it, so if you have sex during that time, your condom or vaginal diaphragm could break."

Answered by AI

What is Clindesse used for?

"This medication is used to treat bacterial vaginosis, a type of vaginal infection, in women who are not pregnant. Clindamycin, an antibiotic, works by stopping the growth of bacteria."

Answered by AI

Clinical Trials for Clindesse

Image of MedStar Washington Hospital Center in Washington D.C., United States.

SESAME Procedure for Hypertrophic Cardiomyopathy

21 - 100
All Sexes
Washington D.C., United States

This is an early study of a catheter-based minimally invasive procedure called SESAME to slice thick heart muscle as described below. Excessively-thick heart muscle can cause serious heart disease, especially heart failure with preserved ejection fraction, which causes shortness of breath and heart failure symptoms such as edema (swelling) and pulmonary congestion (lung water). Specific circumstances of excessively-thick heart muscle can block outflow of blood from the main heart pumping chamber (left ventricle). We developed a catheter technique called SESAME (SEptal Scoring Along Midline Endocardium) to slice the excessively-thick heart muscle causing such problems. SESAME can be used in patients who have symptoms related to excessively-thick heart muscle in a part of the heart that restricts blood ejection from the heart; the problem is called "left ventricular outflow tract obstruction (LVOTO)." One group of patients who might benefit from SESAME suffer from a common inherited heart muscle disease called "hypertrophic cardiomyopathy (HCM)." Patients with HCM and symptoms from LVOTO can be treated with medications, open heart surgery, or catheter-based destruction of heart muscle in "alcohol septal ablation." If these treatments fail or are not suitable, then SESAME may be an option, because it resembles surgery treatment without open heart surgery. Other groups of patients that might benefit are those with heart valve diseases, of the mitral or of the aortic valve, or both, along with excessively-thick heart muscle. These patients may be poor candidates for standard surgical valve repair or replacement because of high risk of complications or death. Such patients might be eligible for non-surgical transcatheter mitral valve replacement, either standard or unapproved ("off-label") or research ("investigational"), but are poor candidates because of risk of LVOTO. Moreover, about half have LVOTO making heart valve symptoms worse. Treating the LVOTO alone may improve symptoms enough that heart valve treatment can be delayed or avoided. This is a sponsor-investigator IDE study of SESAME performed at a small number of centers that have adopted the technique in the practice of medicine, in order better to characterize how well it works and whether it is safe. Participating centers already perform SESAME in the practice of medicine using improvised, off-label devices. This protocol allows prospective oversight, standardized technique constraints, central imaging review, independent monitoring, and formal safety adjudication. In addition, the investigational protocol does not function as the gatekeeper for access to SESAME. The investigators are not affiliated with the guidewire manufacturer and do not seek marketing approval or clearance for SESAME.

Waitlist Available
Has No Placebo

MedStar Washington Hospital Center (+8 Sites)

Robert J Lederman, M.D.

Image of UCSF at Zuckerberg San Francisco General Hospital in San Francisco, United States.

Psilocybin for Methamphetamine Addiction and HIV/AIDS

25 - 64
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn whether it is possible to use psilocybin in combination with motivational support therapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in people with HIV who are seeking to stop using methamphetamine. The main questions it aims to answer are: * Do people with HIV and MeUD find psilocybin with motivational support therapy feasible and acceptable as a potential treatment? * Is psilocybin safe and tolerable among people with HIV and MeUD? Participants will: * Be randomly assigned to receive a single monitored dose of either 25 mg (higher dose) or 5 mg (lower dose) psilocybin * Have 3 preparation and 3 integration motivational support therapy visits before and after the psilocybin dosing session. * Report their methamphetamine use prior to, during, and up to 3 months following the intervention * Optionally receive one additional open-label 25 mg psilocybin session after the 4-week assessment, if eligible

Phase 2
Waitlist Available

UCSF at Zuckerberg San Francisco General Hospital

Nicky J. Mehtani, MD, MPH

Image of University of South Carolina in Columbia, United States.

mHealth Technology for HIV

16 - 25
All Sexes
Columbia, SC

Youth living with HIV (YLHIV) face barriers to engagement and retention in HIV care, show poor medication adherence, and often fail to achieve and maintain viral suppression. YLHIV in the southern United States have particularly poor care engagement outcomes. South Carolina is one of nine states identified as "key drivers" of the US HIV epidemic, and HIV rates for youth in South Carolina have risen in recent years. Tailored interventions are urgently needed to improve outcomes for this population. One promising approach is to reach YLHIV via mobile Health (mHealth) technology, yet few efforts have sought to tailor mHealth interventions to the needs of YLHIV in the southern US. Thus, the scientific objective of this study is to pilot test a new mHealth intervention, called MindBodyU, designed to increase engagement/retention in care and ART adherence among YLHIV in South Carolina. In this study, investigators will evaluate the feasibility, acceptability, and initial efficacy of the mHealth intervention with a six-month pilot trial with 40 YLHIV in South Carolina.

Waitlist Available
Has No Placebo

University of South Carolina

Have you considered Clindesse clinical trials?

We made a collection of clinical trials featuring Clindesse, we think they might fit your search criteria.
Go to Trials
Image of My Brother's Keeper, Inc. in Ridgeland, United States.

Integrated Health Services for HIV

18 - 45
All Sexes
Ridgeland, MS

The goal of this clinical trial is to learn whether integrating routine, opt-out HIV and STI testing and pre-exposure prophylaxis (PrEP) navigation into primary care increases use of these services among adults ages 18 to 45 receiving care at Federally Qualified Health Centers in Mississippi. The main questions it aims to answer are: 1. Does the integrated model increase HIV and STI testing compared with standard care? 2. Does the integrated model increase PrEP navigation activity for eligible patients? 3. How do patients and clinic staff experience the integrated model in terms of satisfaction, comfort discussing sexual health, and feasibility in daily workflows? Researchers will compare a standard-care period to a period when the integrated model is in place to see if the integrated model improves service use and patient experience. Participants will: 1. Receive usual primary care, with HIV/STI testing and PrEP discussions offered as a routine, opt-out part of care during the integrated period 2. Be invited, if eligible, to complete a brief survey about their clinic experience 3. For staff, be invited to take part in a short survey or interview about clinic workflows and the integrated model

Waitlist Available
Has No Placebo

My Brother's Keeper, Inc.

June A Gipson, PhD

Image of New Jersey Community Research Initiative in Newark, United States.

AI-DBT for Suicide Prevention in HIV/AIDS

18+
All Sexes
Newark, NJ

One in four older persons living with HIV/AIDS (PLWHA) report at least one suicide attempt in their lifetime, and the risk for death by suicide is 100 times higher in PLWHA than in the general population. Currently, there are no behavioral interventions that specifically address suicide prevention for older PLWHA, despite their unique biopsychosocial and structural risk factors. Through this work, investigators will adapt Dialectical Behavior Therapy, an evidence-based intervention for suicide prevention, for patients with PLWHA to be delivered by an AI-powered conversational Agent developed by our industry partner, Empower Health. Investigators will then pilot test the feasibility, usability, acceptability and preliminary efficacy to improve self-efficacy to manage negative emotions in n=50 older adults living with HIV/AIDS.

Recruiting
Has No Placebo

New Jersey Community Research Initiative (+1 Sites)

Elissa Kozlov, PhD

Have you considered Clindesse clinical trials?

We made a collection of clinical trials featuring Clindesse, we think they might fit your search criteria.
Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL

The goal of this study is to examine two types of olfactory interventions (conventional olfactory training vs scented marker training) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Conventional Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Scented Marker Training at Home -- Several marker scents in which they will smell twice a day for 8 weeks.

Phase 2
Recruiting

University of Alabama at Birmingham

Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA

This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.

Waitlist Available
Has No Placebo

Los Angeles General Medical Center

Hayoun Lee, PhD

Image of University of California, San Francisco in San Francisco, United States.

Guaranteed Income for HIV Care

18+
All Sexes
San Francisco, CA

The goal of this clinical trial is to understand the implementation requirements and potential health impacts of a guaranteed income (GI) intervention targeting people living with HIV with criminal legal involvement (PWH-CLI). The main questions it aims to answer are: * How acceptable is a GI intervention, and its intervention components, among PWH-CLI participants and stakeholders? * How feasible is a GI intervention for PWH-CLI? What are the implementation barriers and opportunities for this intervention? * What is the preliminary efficacy of the GI intervention on improving HIV care outcomes for PWH-CLI? Researches will compare study engagement and study outcomes across three randomization arms (A: receive full GI amount as one lump sum payment; B: receive full GI amount split over nine monthly installments; C: participant chooses whether to receive GI as lump sum payment or monthly installments). HIV care outcomes will be compared against a retrospective cohort of PWH-CLI patients as historical controls. Participants will: * Be randomized to receive GI intervention as a lump sum payment or monthly installment (over nine months) or choose their preference. * Complete 3 surveys throughout study follow up to assess experience with the intervention, experience with social services and benefits programs, experience with the criminal legal system, and HIV care outcomes. * Be interviewed by the research team to further understand the experience with the intervention.

Waitlist Available
Has No Placebo

University of California, San Francisco

Paul D Wesson, PhD

Have you considered Clindesse clinical trials?

We made a collection of clinical trials featuring Clindesse, we think they might fit your search criteria.
Go to Trials